Heart failure (HF) remains a major cause of morbidity and mortality despite substantial advances in disease-modifying therapy, and clinical improvement does not necessarily indicate complete restoration of myocardial homeostasis. Increasing evidence suggests that inflammatory, stromal, vascular, metabolic, and mitochon...
T. Urbanowicz, M. Kowalewski, Aneta Klotzka et al.· Cells· 0 citations
Background: ELAFIN (peptidase inhibitor 3, PI3) is an endogenous inhibitor of neutrophil elastase and proteinase 3, but its circulating profile in type 2 diabetes mellitus (T2DM) and cardiovascular disease remains poorly characterized. We investigated circulating ELAFIN in patients undergoing elective coronary angiogra...
B. Krasińska, T. Urbanowicz, M. Kang et al.· Antioxidants· 0 citations
Patients with a higher thromboembolic risk gain the most benefits from concomitant SA, with patients at higher thromboembolic risk gaining the most benefits from concomitant SA.
Mariusz Kowalewski, G. Raffa, Jakub Batko et al.· Innovations· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.